The 2023 IOF Medal of Achievement was awarded to Professor Jean-Yves Reginster at the Opening of the World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO 2023) on May 4th, 2023.
The IOF Medal of Achievement honours individuals who have significantly advanced the field of osteoporosis through their original and outstanding scientific contributions, and whose work has helped to increase understanding and awareness of osteoporosis. Candidates are nominated by members of IOF’s Committee of Scientific Advisors (CSA) and the winner is selected by the Chair of the CSA with the approval of the IOF Executive Committee.
In awarding the IOF Medal of Achievement, Professor Nicholas Harvey, Chair of the IOF Committee of Scientific Advisors stated,
“I am honoured to present this Award to Jean-Yves Reginster, whose research and extraordinary commitment to advancing best practice, education and advocacy have made major and lasting impacts on our field. As a co-founder of IOF and President of ESCEO, he has been instrumental in promoting the urgent need to address osteoporosis at the global level, culminating in the recently inaugurated five-year collaboration between ESCEO and the World Health Organization.”
Jean-Yves Reginster M.D., Ph.D. is currently Outstanding Professor of Epidemiology, Public Health and Health Economics as well as Professor of Bioethics and Societal Medicine at the University of Liège where he also serves as the Honorary Chair of the Bone and Cartilage Metabolism Unit. He is the Director of the Division of Public Health, Epidemiology and Health Economics at the University of Liège and Director of the WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. He is an active researcher who has authored more than 900 publications, mainly dedicated to the pathophysiology, epidemiology, health economics, clinical and translational aspects of osteoporosis, osteoarthritis, frailty and sarcopenia. Among his other professional activities, Professor Reginster is President of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), Co-Founder and Board member of the International Osteoporosis Foundation (IOF), where he serves as Chair of the Committee of National Societies (CNS). He previously served as Adjunct Professor of Medicine at Georgetown University Medical Center, Washington DC, USA. He was the Belgian alternate member for the Efficacy Working Party at the Committee for Human Proprietary Medicines (CHMP) of the European Medicines Agency (EMA) where he acted as rapporteur/co-rapporteur for the guidelines for the registration of drugs to be used in the management of osteoporosis and osteoarthritis. He is also a former member of the Belgian Commission for Registration of Drugs, served at the Belgian Commission for Reimbursement of Drugs (Commission de Transparence), and has been a Board Member of the Osteoarthritis Society International (OARSI).
World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO Barcelona 2023)
Held jointly by IOF and ESCEO, the Congress takes place in Barcelona, Spain from May 4-7, 2023. WCO-IOF-ESCEO is the world’s largest annual forum for the presentation of clinical research and new advances in the prevention and management of bone, muscle and joint disorders, including sarcopenia and frailty. For complete information visit www.wco-iof-esceo.org #OsteoCongress
The International Osteoporosis Foundation (IOF) is the world’s largest nongovernmental organization dedicated to the prevention, diagnosis, and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as more than 315 patient, medical and research organizations, work together to make fracture prevention and healthy mobility a worldwide heath care priority. www.osteoporosis.foundation @iofbonehealth
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. www.esceo.org